Patents Assigned to U3 Pharma GmbH
  • Publication number: 20170166973
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co., Ltd., U3 Pharma GmbH, AMGEN, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
  • Publication number: 20170166654
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: October 19, 2016
    Publication date: June 15, 2017
    Applicants: Daiichi Sankyo Co. Ltd., U3 Pharma GmbH, Kinki University, Amgen, Inc.
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20170021031
    Abstract: To provide an antitumor drug having excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. Provided is an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER3 antibody via a linker having a structure represented by the formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— or -L1-L2-LP- (the anti-HER3 antibody is connected to the terminal of L1, the antitumor compound is connected to the carbonyl group of —(CH2)n2-C(?O)— moiety or the C terminal of LP, with the nitrogen atom of the amino group at position 1 as a connecting position).
    Type: Application
    Filed: October 4, 2016
    Publication date: January 26, 2017
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, U3 PHARMA GMBH
    Inventors: Thore HETTMANN, Reimar ABRAHAM, Sabine BLUM, Suguru UENO
  • Publication number: 20160222126
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: January 18, 2016
    Publication date: August 4, 2016
    Applicants: U3 PHARMA GMBH, AMGEN, INC.
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky, Mike Rothe
  • Publication number: 20160168264
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Applicants: U3 PHARMA GMBH, AMGEN, INC.
    Inventors: MIKE ROTHE, MARTIN TREDER, ERIC BORGES, SUSANNE HARTMANN, LARRY L. GREEN
  • Publication number: 20160161491
    Abstract: The present invention provides methods for the determination of the activation level of Receptor Tyrosine kinases, e.g. phosporylated HER3, for the selection of patients for disease treatment. Methods are also provided for the evaluation of the biological and pharmacodynamic effects of an active substance and/or its efficacy in disease treatment, utilizing a tissue sample from a test subject, for example tumor material or normal tissue such as skin or hair follicle. Further, methods for the treatment of HER receptor-associated diseases are disclosed.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 9, 2016
    Applicant: U3 PHARMA GMBH
    Inventors: Mike ROTHE, Martin TREDER
  • Patent number: 9284379
    Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: March 15, 2016
    Assignee: U3 Pharma GmbH
    Inventors: Johannes Bange, Jens Niewoehner, Patricia Aus Dem Siepen, Mike Rothe
  • Patent number: 9249230
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: February 2, 2016
    Assignees: U3 Pharma GmbH, Amgen Inc.
    Inventors: Mike Rothe, Martin Treder, Eric Borges, Susanne Hartmann, Larry L. Green
  • Patent number: 9101760
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: August 11, 2015
    Assignees: U3 Pharma GmbH, Amgen, Inc.
    Inventors: Thore Hettmann, Daniel J. Freeman, Robert Radinsky
  • Publication number: 20150152508
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at an mRNA level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at an mRNA level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: June 4, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN
  • Publication number: 20150152193
    Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Application
    Filed: December 8, 2014
    Publication date: June 4, 2015
    Applicant: U3 PHARMA GMBH
    Inventors: Thore HETTMANN, Jens NIEWOEHNER, Jens RUHE, Peter WIRTZ, Kerstin SELLE, Esther ZWICK-WALLASCH, Mike ROTHE
  • Publication number: 20150147326
    Abstract: The present invention is directed to methods of identifying and treating a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and administering a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as high. The present invention is also directed to methods of identifying a human subject harboring a tumor or other disease comprising assessing HRG gene expression at a protein level in the human subject and withholding a treatment comprising an anti-HER3 antibody to the human subject whose HRG gene expression at a protein level is assessed as low.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 28, 2015
    Applicants: Daiichi Sankyo Company, Limited, U3 Pharma GmbH, Kinki University
    Inventors: Matthias SCHNEIDER, Sabine BLUM, Renee Jeanne MENDELL-HARARY, Daniel J. FREEMAN, Robert Allen BECKMAN, Xiaoping JIN, Kimio YONESAKA, Kazuhiko NAKAGAWA
  • Publication number: 20150037336
    Abstract: The present application relates to the combined use of an antigen-binding protein that binds HB-EGF and an EGFR tyrosine kinase inhibitor in medical treatment.
    Type: Application
    Filed: February 20, 2013
    Publication date: February 5, 2015
    Applicant: U3 PHARMA GMBH
    Inventor: Esther Zwick Wallasch
  • Publication number: 20150037323
    Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Application
    Filed: July 15, 2014
    Publication date: February 5, 2015
    Applicant: U3 PHARMA GMBH
    Inventors: Peter WIRTZ, Jens RUHE, Takeshi TAKIZAWA, Tomoko TAKAYAMA
  • Patent number: 8933202
    Abstract: The present invention refers to antibodies, particularly to monoclonal antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Grant
    Filed: November 12, 2008
    Date of Patent: January 13, 2015
    Assignee: U3 Pharma GmbH
    Inventors: Thore Hettmann, Jens Niewöhner, Jens Ruhe, Peter Wirtz, Kerstin Selle, Esther Zwick-Wallasch, Mike Rothe
  • Patent number: 8841424
    Abstract: The present invention refers to monoclonal humanized antibodies, which bind to the extracellular domain of the AXL receptor tyrosine kinase and which at least partially inhibit AXL activity.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: September 23, 2014
    Assignee: U3 Pharma GmbH
    Inventors: Peter Wirtz, Jens Ruhe, Takeshi Takizawa, Tomoko Takayama
  • Patent number: 8828382
    Abstract: Provided herein are antigen binding proteins, e.g., human and/or monoclonal antibodies that have affinity for heparin-binding epidermal growth factor-like growth factor (HB-EGF) and neutralize the biological functions of this growth factor.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: September 9, 2014
    Assignees: U3 Pharma GmbH, Amgen Inc.
    Inventors: Mike Rothe, Norbert Prenzel, Eric Borges, Thore Hettmann, Esther Zwick-Wallasch, Orit Foord
  • Patent number: 8771695
    Abstract: The present invention relates to binding proteins that bind to HER-3 and polynucleotides encoding the same. Expression vectors and host cells comprising the same for the production of the binding protein of the invention are also provided. In addition, the invention provides compositions and methods for diagnosing and treating diseases associated with HER-3 mediated signal transduction and/or its ligand heregulin.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: July 8, 2014
    Assignees: U3 Pharma GmbH, Amgen, Inc.
    Inventors: Mike Rothe, Martin Treder, Susanne Hartmann, Daniel J. Freeman, Robert Radinsky, Eric Borges
  • Publication number: 20140017166
    Abstract: Described herein are materials and methods for treating subjects having a HER-3 associated disease, by administering a first agent that binds to HER-3, in combination with a second agent that binds and/or inhibits another member of the HER family. The first and the second agent may be a biologic, such as an antigen-binding protein, or a small molecular tyrosine kinase inhibitor, for example.
    Type: Application
    Filed: April 25, 2013
    Publication date: January 16, 2014
    Applicants: AMGEN, INC., U3 PHARMA GMBH
    Inventors: U3 PHARMA GMBH, AMGEN, INC.
  • Publication number: 20130183319
    Abstract: The present invention relates to FGFR4 antibodies including fragments or derivatives thereof and the polynucleotides encoding the antibodies. Expression vectors and host cells comprising the polynucleotides are provided. Further, the invention refers to pharmaceutical compositions comprising the FGFR4 antibodies and methods for the treatment, prevention or diagnosis of disorders associated with FGFR4 expression.
    Type: Application
    Filed: January 18, 2013
    Publication date: July 18, 2013
    Applicant: U3 PHARMA GMBH
    Inventor: U3 PHARMA GMBH